S&P 500   4,207.15 (+0.04%)
DOW   32,967.71 (-0.38%)
QQQ   350.09 (+0.49%)
AAPL   177.34 (+1.09%)
MSFT   331.61 (-0.38%)
META   264.64 (+0.99%)
GOOGL   123.75 (-0.69%)
AMZN   121.30 (+0.99%)
TSLA   199.24 (+3.14%)
NVDA   402.50 (+3.35%)
NIO   7.38 (-4.16%)
BABA   78.61 (-2.91%)
AMD   126.05 (-0.77%)
T   15.63 (+0.84%)
F   12.68 (+4.88%)
MU   72.67 (-1.70%)
CGC   0.87 (-1.32%)
GE   101.98 (-0.74%)
DIS   87.33 (-1.09%)
AMC   4.57 (-1.51%)
PFE   37.06 (-1.44%)
PYPL   61.06 (+1.39%)
NFLX   391.12 (+3.23%)
S&P 500   4,207.15 (+0.04%)
DOW   32,967.71 (-0.38%)
QQQ   350.09 (+0.49%)
AAPL   177.34 (+1.09%)
MSFT   331.61 (-0.38%)
META   264.64 (+0.99%)
GOOGL   123.75 (-0.69%)
AMZN   121.30 (+0.99%)
TSLA   199.24 (+3.14%)
NVDA   402.50 (+3.35%)
NIO   7.38 (-4.16%)
BABA   78.61 (-2.91%)
AMD   126.05 (-0.77%)
T   15.63 (+0.84%)
F   12.68 (+4.88%)
MU   72.67 (-1.70%)
CGC   0.87 (-1.32%)
GE   101.98 (-0.74%)
DIS   87.33 (-1.09%)
AMC   4.57 (-1.51%)
PFE   37.06 (-1.44%)
PYPL   61.06 (+1.39%)
NFLX   391.12 (+3.23%)
S&P 500   4,207.15 (+0.04%)
DOW   32,967.71 (-0.38%)
QQQ   350.09 (+0.49%)
AAPL   177.34 (+1.09%)
MSFT   331.61 (-0.38%)
META   264.64 (+0.99%)
GOOGL   123.75 (-0.69%)
AMZN   121.30 (+0.99%)
TSLA   199.24 (+3.14%)
NVDA   402.50 (+3.35%)
NIO   7.38 (-4.16%)
BABA   78.61 (-2.91%)
AMD   126.05 (-0.77%)
T   15.63 (+0.84%)
F   12.68 (+4.88%)
MU   72.67 (-1.70%)
CGC   0.87 (-1.32%)
GE   101.98 (-0.74%)
DIS   87.33 (-1.09%)
AMC   4.57 (-1.51%)
PFE   37.06 (-1.44%)
PYPL   61.06 (+1.39%)
NFLX   391.12 (+3.23%)
S&P 500   4,207.15 (+0.04%)
DOW   32,967.71 (-0.38%)
QQQ   350.09 (+0.49%)
AAPL   177.34 (+1.09%)
MSFT   331.61 (-0.38%)
META   264.64 (+0.99%)
GOOGL   123.75 (-0.69%)
AMZN   121.30 (+0.99%)
TSLA   199.24 (+3.14%)
NVDA   402.50 (+3.35%)
NIO   7.38 (-4.16%)
BABA   78.61 (-2.91%)
AMD   126.05 (-0.77%)
T   15.63 (+0.84%)
F   12.68 (+4.88%)
MU   72.67 (-1.70%)
CGC   0.87 (-1.32%)
GE   101.98 (-0.74%)
DIS   87.33 (-1.09%)
AMC   4.57 (-1.51%)
PFE   37.06 (-1.44%)
PYPL   61.06 (+1.39%)
NFLX   391.12 (+3.23%)

IVERIC bio (ISEE) Price Target & Analyst Ratings

$37.67
-0.09 (-0.24%)
(As of 12:40 PM ET)
Compare
Today's Range
$37.65
$37.85
50-Day Range
$22.64
$38.05
52-Week Range
$8.85
$38.25
Volume
553,593 shs
Average Volume
3.18 million shs
Market Capitalization
$5.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.45

IVERIC bio Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 11 Analyst Ratings

Consensus Analyst Price Target

$27.45
-27.12% Downside
High Prediction$35.00
Average Prediction$27.45
Low Prediction$18.00
TypeCurrent
5/30/22 to 5/30/23
1 Month Ago
4/30/22 to 4/30/23
3 Months Ago
3/1/22 to 3/1/23
1 Year Ago
5/30/21 to 5/30/22
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
10 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$27.45$27.45$27.30$24.14
Predicted Upside-27.12% Downside61.25% Upside73.68% Upside72.93% Upside
Get IVERIC bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ISEE and its competitors with MarketBeat's FREE daily newsletter.


ISEE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ISEE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IVERIC bio Stock vs. The Competition

TypeIVERIC bioMedical CompaniesS&P 500
Consensus Rating Score
2.09
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside-27.14% Downside1,320.37% Upside197.14% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/5/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
5/4/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral
5/3/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
5/2/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Caufield
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/1/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral
5/1/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight
5/1/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral
5/1/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
2/21/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Y. Zhi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral$17.00 ➝ $19.00-13.44%
11/10/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$30.00 ➝ $20.00+2.51%
6/8/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$18.00+63.93%
(Data available from 5/30/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ISEE Price Target - Frequently Asked Questions

What is IVERIC bio's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for IVERIC bio stock is Hold based on the current 10 hold ratings and 1 buy rating for ISEE. The average twelve-month price prediction for IVERIC bio is $27.45 with a high price target of $35.00 and a low price target of $18.00. Learn more on ISEE's analyst rating history.

Do Wall Street analysts like IVERIC bio more than its competitors?

Analysts like IVERIC bio less than other Medical companies. The consensus rating for IVERIC bio is Hold while the average consensus rating for medical companies is Buy. Learn more on how ISEE compares to other companies.

Is IVERIC bio being downgraded by Wall Street analysts?

Over the previous 90 days, IVERIC bio's stock had 8 downgrades by analysts.

Does IVERIC bio's stock price have much upside?

According to analysts, IVERIC bio's stock has a predicted upside of 60.92% based on their 12-month price targets.

What analysts cover IVERIC bio?

IVERIC bio has been rated by Credit Suisse Group, Guggenheim, HC Wainwright, Morgan Stanley, Robert W. Baird, Stifel Nicolaus, UBS Group, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ISEE) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -